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Background: The Affordable Care Act (ACA) requires that privately insured women can obtain contraceptive services and supplies without
cost sharing. This may substantially affect women who prefer an intrauterine device (IUD), a long-acting reversible contraceptive, because of
high upfront costs that they would otherwise face. However, imperfect enforcement of and exceptions to this provision could limit its effect.
Study design: We analyzed administrative data for 417,221 women whose physicians queried their insurance plans from January 2012 to
March 2014 to determine whether each woman had insurance coverage for a hormonal IUD and the extent of that coverage.
Results: In January 2012, 58% of women would have incurred out-of-pocket costs for an IUD, compared to only 13% of women in March
2014. Differentials by age and region virtually dissolved over the period studied, which suggests that the ACA reduced inequality among
insured women.
Conclusions: Our findings suggest that the cost of hormonal IUDs fell to US$0 for most insured women following the implementation of
the ACA.
Implications: Financial barriers to one of the most effective methods of contraception fell substantially following the ACA. If more women
interested in this method can access it, this may contribute to a decline in unintended pregnancies in the United States.
© 2016 TheAuthors. Published byElsevier Inc. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Contraception; Healthcare reform; Out-of-pocket costs; IUD; LARC; Insurance1. Introduction
In the United States, 43 million women are at risk of
unintended pregnancy, and 39 million of them (90%) use
contraception [1,2]. Some 30 million (78% of contraceptors)
use a method more effective than condoms, and 4 million
(10%) use an intrauterine device (IUD), while fewer than a half
million use another long-acting reversible method [1,3]. Fewer
than 1%ofwomenwho use IUDswill become pregnantwithin
a year, in contrast to 18% of women who use condoms to
prevent pregnancy, and 9% of women who use the pill [4].
Women who would otherwise prefer the IUD face barriers
that can lead them to use less effective contraceptives; these
include high upfront costs that can exceed a thousand dollars
[5–11]. Greater uptake of the IUD and the implant preceded
fewer births in Colorado and fewer abortions in Iowa, and in⁎ Corresponding author. Guttmacher Institute, 125 Maiden Lane, 7th
Floor, New York, NY 10038, USA. Tel.: +1-646-438-8774.
E-mail address: jbearak@guttmacher.org (J.M. Bearak).
http://dx.doi.org/10.1016/j.contraception.2015.08.018
0010-7824/© 2016 The Authors. Published by Elsevier Inc. This is an open access article undeSt. Louis, teenagers provided these methods at no-cost
exhibited rates of pregnancy, birth and abortion far lower
than the national average [8,12,13].
Insurance mandates may help women to access the contra-
ceptive of their choice. In 1993, 32% of insurers covered the IUD
[14].By2002, in part because insurancemandates came into effect
in many states, this increased to 94% [14]. However, when an
insurance company covers a contraceptive, a woman may still
incur costs— for example, womenmay incur copayments for the
prescription and visits to a doctor’s office or clinic.
A provision of the Affordable Care Act (ACA) requires
that patients do not face out-of-pocket costs for contraceptive
services and supplies at in-network providers. This provision
matters particularly in the context of the high upfront costs of
an IUD. This ACA mandate phased in starting in August
2012, and it took effect for many health insurance plans in
January 2013. This may improve the ability of millions of
women to afford safe and effective contraception [15].
The ACA can affect insurers exempt from state mandates,
whereas states lacked authority over self-funded employerr the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
140 J.M. Bearak et al. / Contraception 93 (2016) 139–144plans. However, other exceptions may limit the effect of the
ACA’s contraceptive coverage mandate. These include
grandfathered insurance plans and the contraceptive exclu-
sion. Grandfathered plans are those that came into being no
later than March 2010 and have not seen substantial benefit
changes since then [16]. The contraceptive exclusion
exempts certain religious employers from the ACA’s
contraceptive coverage provision. As such, even if insurance
companies adhere perfectly to the law, some women covered
by private insurance may still have to pay the full cost of the
IUD and other contraceptives.
Women interested in an IUD may face a higher financial
burden if their insurance plan requires out-of-pocket costs. In
addition to the cost of the device itself and the initial doctor’s
visit, women may also face costs to insert and remove their
IUD [5–7,10,17]. In 2002, a year after the hormonal IUD
came on the market (complementing the nonhormonal
copper IUD, which had been available in the United States
since 1988), 94% of insurers covered IUDs, but cost sharing
continued to make the IUD unaffordable for many women
interested in it [8,9,14].
To understand the impact of the ACA’s contraceptive
coverage provision on IUD cost sharing, we would need to
know what costs women faced before and after the ACA.
Unfortunately, the extant literature on IUD cost sharing
after the ACA went into effect is limited. One analysis
estimated that full coverage increased from 45% to 62%
after the ACA, based on data from 165 privately insured
women [18]. Data from the National Survey of Family
Growth (NSFG), the best available representative survey of
women’s contraceptive behavior, do not indicate when
women obtained their IUDs or how much they paid. Even if
the NSFG asked women how much they paid, this
information would not provide us the percentage of
women seeking an IUD who faced out-of-pocket costs: if
cost inhibits IUD uptake, the extant data will under-
represent women with higher costs [8–10]. All surveys that
measure cost based on women who obtained IUDs share
this limitation, as do claims data. Finally, none of these
surveys address the effect of the contraceptive exclusion,
which exempts certain religious employers from providing
full coverage.
To help address these limitations, we analyzed data on
insurance inquiries; these show what an insured woman
would have paid if she had chosen to obtain an IUD, between
January 2012 and March 2014, a period covering the
introduction of the ACA’s contraceptive coverage provision
and its initial implementation for many plans.1 The data record whether patients were subject to cost sharing, and if
o, what the copayment or coinsurance rate was and not what providers
harge.
2 This could arise if, for example, a woman’s coverage is not yet active
r is no longer active, but the data do not record this. Because our goal was
n analysis of insured women’s IUD benefits, we excluded these women.2. Materials and methods
2.1. Data
Bayer HealthCare, the manufacturer of the Mirena® and
Skyla® IUDs, used by some 3 of 4 million American IUD
users [3] offers a voluntary “benefit inquiry” service tohealthcare providers to determine the type and extent of a
patient’s insurance coverage for an IUD and whether the
patient’s insurance company requires cost sharing. Bayer
utilizes an outside benefits-verification contractor and does not
obtain the data directly. Within a few days after a healthcare
provider’s inquiry, typewritten reports with a narrative
summary of coverage are faxed by the contractor to healthcare
providers, and details of each benefit inquiry are recorded in
the contractor’s database1. Though healthcare providers can
pursue this information independently, they may elect to use
this free service to reduce their administrative caseload.
The dataset we obtained contained 444,316 women
whose physicians inquired about a Mirena or Skyla IUD
between January 2012 and March 2014. Of these, we
excluded 27,095 women from the analysis because they were
minors (4,577, in order to focus on adults who were likely to
have their own insurance), they had no insurance (11,363)2,
a woman’s insurer would not reveal benefit information to a
third party (10,382), women or their healthcare providers did
not completely fill out the form (763), or the healthcare
provider canceled the inquiry (10). The resulting number of
cases we analyzed was 417,221.
The analysis period includes time both before and after
the ACA’s key provision regarding contraceptive coverage
took effect, which allowed us to study its impact. We
hypothesized that there would be a sharp decline in the
percentage of women subject to cost sharing in the first
quarter of 2013, since patients with existing coverage
typically sign up for new plans or renew their insurance at
the beginning of a calendar year, and January 2013 was the
first new year after the implementation of the ACA’s
contraceptive coverage provision.
2.2. Methods
We analyzed changes between January 2012 and March
2014 in the percentage of women who would have had
out-of-pocket costs for a hormonal IUD. The ACA’s
contraceptive coverage provision came into effect in August
2012, but did not affect most women until January 2013, as
most employer-based insurance plans are typically renewed
on January 1.
For 2013 onward (n=231,086), we assessed how these
results were affected when taking into account two
additional factors that affect cost sharing: copayment for
insertion and cost sharing owing to a deductible (data not
available in 2012). This may affect our results as, for
example, women whose insurers covered the cost of the
device might not have interpreted the ACA mandate to apply
to services as well as supplies.s
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ig. 1. Percentage of women who would have had out-of-pocket costs for a
ormonal IUD, by month. Note: The lighter line begins in January 2013
ecause the 2012 data do not contain insertion copayments and deductible
pplicability.
141J.M. Bearak et al. / Contraception 93 (2016) 139–144We estimated trends for all women by month in whether a
woman’s insurance coverage required cost sharing. We also
estimated trends by quarter for age and region subgroups to
examine inequality in coverage before, and after, the ACA
came into effect.
In an analysis of a very large dataset, trivial fluctuations
can reach statistical significance. It is therefore inappropriate
to compare p-values, as, for example, a trivial decline of
0.01%, which might only reflect random fluctuations, may
be described as “statistically” significant [19]. Therefore, we
highlight the substantive size of change over time3.
In order to understand how much women who still have
costs would be required to pay, we also computed cost
estimates at the median and 90th percentiles. A woman’s
out-of-pocket cost is the sum of a fixed copayment and the
product of the IUD’s price and her coinsurance rate.
Unfortunately, we do not know the price that a healthcare
provider would charge a patient for the IUD. Therefore, for
the 13% of women subject to coinsurance, we multiplied
their coinsurance rate by the most recent published estimates
for Mirena’s wholesale price, US$844 [7]. This strategy
understates the actual cost because patients may also be
required to pay for an initial visit to their healthcare provider
and for the device’s insertion.
Finally, the dataset indicates whether a woman’s coverage
was subject to the contraceptive exclusion for religious
employers, and we use this to estimate the percentage of
women without coverage who would have had coverage if
not for this exclusion.2.3. Sensitivity analyses
Of the women in our data, 50,804 have multiple insurers.
We do not know their insurers’ names or why they have
duplicative coverage. We suspect, for example, that some
may have private insurance from their employer, as well as
secondary insurance from Medicaid or their spouse’s
employer. In our main analysis, we assumed that women
with multiple insurers can choose which insurer to use. They
may not have this choice, however4. Therefore, we
performed a sensitivity analysis in which we assume that a
woman with duplicative coverage must use whichever
insurer offers the worst coverage.3 Results of logistic regressions, which compare each month to January
2013 or each quarter to the first quarter of 2013, are available from the
authors upon request.
4 We speculate, for example, that a woman’s employer’s insurance may
be her primary insurer in some cases, and she may also have insurance
from her spouse’s employer; she may have to use her employer’s insurer
even if her spouse’s insurer offers a lower copay. Alternatively, a woman’s
primary insurer may cover the IUD but may require a copayment; if she has
Medicaid, then, Medicaid should cover the copayment.F
h
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a3. Results
The black line in Fig. 1 shows the decreasing percentage
of women who faced out-of-pocket costs for a hormonal IUD
(and at least some cost for its insertion) over the 27 months
between January 2012 and March 2014. In January 2012,
out-of-pocket costs were required of 58% of insured patients;
by March 2014, this number dropped to 13%. The
percentage of women who faced out-of-pocket costs did
not decrease during the first half of 2012; we first observe
decreases toward the end of 2012, as the ACA’s contracep-
tive coverage requirement first took effect for patients
signing up for new health plans. Coverage increased
substantially at the end of 2012, when many patients’ annual
plans were renewed and the ACA took effect for those
without grandfathered plans; the percent with out-of-pocket
costs declined 3 percentage points in December 2012, from
52% to 49%, and 21 points in January 2013, from49% to 28%.
Over the next 15 months, from February 2013 through March
2014, the percentage of women who faced out-of-pocket costs
fell to 13%, or by 1 percentage point per month.
We analyzed whether a woman’s insurer required a
copayment for the device’s insertion or otherwise required
cost sharing due to a deductible from 2013 onwards (as these
data were not available for 2012). The results did not
substantively differ from the trend described above for full
coverage. The gray line in Fig. 1 shows that 16% rather than
13% of women faced out-of-pocket costs for both the device
and its insertion. These estimates of change over time may be
conservative, however, as the percentage of women with
insurers who required them to share in the cost of the device’s
insertion might have been higher in 2012 than in 2013.
Figs. 2 and 3 show trends in IUD coverage by age and
region, respectively. Before the implementation of the ACA
provision, young and Northeastern women experienced
higher levels of coverage than other women; after imple-
mentation, differences by age and region narrowed sharply.
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Fig. 2. In each age group: percentage of women who would have had
out-of-pocket costs for a hormonal IUD, by quarter.
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24 and 40–49 years would have had to pay out of pocket, a
14-point difference (Fig. 2). In Q1 2013, less than a third of
this gap remained (4 points, 24% versus 28%); differences
by age nearly dissolved by the end of the analysis period.
Similarly, in Q1 2012, 53% and 61–64%, respectively, of
women in the Northeast and elsewhere would have had to pay
something out of pocket (Fig. 3). In Q1 2013, four fifths of this
gap remained, and after another year, differences by region
nearly dissolved (to 0–3 points). Differences by region
dissolved as much as differences by age but less rapidly.
Table 1 reports the percentage of women with full
coverage for a hormonal IUD (and at least partial coverage
for its insertion), with partial coverage for the IUD or without
coverage, by quarter, between Q1 2012 and Q1 2014. The
table indicates that very few women in these data had no
coverage at all. Thus, most of the increase in full coverage
appears to be driven by insurance companies moving from
partial to full coverage.10%
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Fig. 3. In each region: percentage of women would have had out-of-pocket
costs for a hormonal IUD, by quarter.Table 1 also reports that the percentage of women in these
data affected by the contraceptive exclusion for religious
employers varies from 0.4% to 2.2% in the five quarters
between January 2013 and January 2014. Dividing the
percentage without coverage due to the contraceptive
exclusion by the percentage of women with no coverage
shows, however, that these 0.4–2.2% of women who sought
an IUD amount to 8.8–37.9% of women who sought an IUD
and had no coverage; this may suggest that a nontrivial portion
of women with interest in an IUD but without any coverage
worked for a religious employer that denies contraceptive
coverage. Considering the wide variation in these numbers,
however, they should be interpreted with caution.
Table 2 reports cost estimates for the IUD itself at themedian
and 90th percentiles. The 90th percentile declines to $169 in the
first quarter of 2013 and to $15 in the first quarter of 2014, from
$844 in the first three quarters of 2012. Median estimates are
much smaller, at $20 in the first half of 2012, and fall to $0 inQ4
2012, as by then fewer than half of women (49.9%) faced
out-of-pocket costs for the IUD itself.
In a sensitivity analysis, we examined the percentage of
women who faced out-of-pocket costs for obtaining an IUD
under the assumption that women with multiple insurers— for
example, backed up by Medicaid — could not rely on the
insurance with the lowest out-of-pocket cost available to them.
In this scenario, 20% of women would have had out-of-pocket
costs for the IUD and insertion in March 2014, compared to
16% as shown in Fig. 1. In both coverage scenarios, 58–59%
faced out-of-pocket costs in January 2012, so this sensitivity
analysis corroborates the overall analysis.4. Discussion
Following implementation of the ACA, we observed a
substantial decline in the percentage of women having to pay
out of pocket for a hormonal IUD and the elimination of cost
disparities by age and region. Potential for further decline
remains, as 13% of women still did not have complete
coverage as of March 2014.
Some of the decrease in women who face costs could
follow from other causes aside from the ACA. However, we
note the complete absence of any trend prior to the point in
time at which the ACA’s provisions came into effect.
Either the ACA reduces differences between the North-
east and other regions or the characteristics of the healthcare
providers who use the benefit inquiry service differ in the
Northeast. If so, then these findings may reflect a
convergence in coverage not by region but by unobserved
socioeconomic characteristics. We cannot identify effects by
individual characteristics such as income or race, but trends
by region suggest that IUD coverage increased substantially
under ACA throughout the United States.
To address the representativeness of the benefit inquiry
data, we compared the available demographics — age and
geographic region — to U.S. Census data and the NSFG.
Table 1
Percentage of women with different levels of coverage for a hormonal IUD and percentage affected by the contraceptive exclusion for religious employers, by
quarter.
2012 2013 2014
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
Percentage of women with coverage
No coverage 11.0 11.7 10.6 9.2 5.7 5.2 4.5 4.1 3.3
Coverage but with cost sharing 47.8 47.7 46.1 42.9 21.4 17.2 13.0 14.6 10.3
No-cost coverage for the device and coverage for the insertion 41.2 40.6 43.3 47.9 72.8 77.6 82.5 81.4 86.4
Contraceptive exclusion
Percentage of women – – – – 2.2 1.5 0.6 0.4 0.7
Percentage of women with no coverage – – – – 37.9 28.6 13.7 8.8 21.6
N (1000s) 49.6 46.8 46.0 43.6 45.6 51.1 46.2 41.5 46.7
Note: The data do not contain information on the contraceptive exclusion in 2012.
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not differ significantly from all women of reproductive age.
With regard to geography, the comparisons indicate that the
benefit inquiry data overrepresent women in the Northeast
and underrepresent women in the West, although women in
the West are more likely to have an IUD in the NSFG and in
a recent Centers for Disease Control and Prevention analysis
of services provided to teenagers in Title X clinics [3,20];
this may reflect differences by region in the use of the benefit
inquiry service.
We note several limitations of our approach. A key
limitation is that we rely upon both the manufacturer of the
hormonal IUDs and the manufacturer’s benefits-verification
contractor for the data’s authenticity and accuracy. We also
cannot determine how many of the 13% of women who
remain without complete coverage in March 2014 do so
because of imperfect adherence to the ACA requirement or
because they have a grandfathered insurance plan. Evidence
of imperfect adherence leads advocates like the National
Women’s Law Center to publish advice to women faced with
costs in spite of the federal mandate [21–23]. Also, as
previously noted, these data do not represent all women
seeking Mirena or Skyla, nor do we know the percentage of
these women who actually went on to obtain an IUD or the
number of IUDs sold. Finally, we expect but cannot confirm
that these data predominantly represent women with private
insurance, as a doctor familiar with the public insurance
plans within his or her state would likely know a publicly
insured woman’s coverage. While we note these limitations,
our findings corroborate similar results from other studies
that analyze other contraceptives [17,18].Table 2
Median and 90th percentile cost estimates for a hormonal IUD, by quarter.
2012 2013 2014
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
Median 20 20 15 0 0 0 0 0 0
90th percentile 844 844 844 338 169 169 84 50 15Earlier studies reported that most women with private
insurance had at least partial coverage [10,14,17,18,24], but
these studies could have underestimated the number of
women with no coverage because they analyzed women who
obtained an IUD, and women who discovered that their
insurance did not cover an IUD might not obtain one. In
contrast to these earlier studies, our results are not biased by
this limitation.
Noticeable gaps in the percentage of women who are
covered and not subject to cost sharing, between women by
region and women by age, dissolved after the ACA took
effect. This convergence suggests that the ACA reduced
inequality among insured women. Were race or income
available in these data, it would have been interesting to test
whether race or income inequality in coverage declined over
time. We believe that this is worth further study.
Our study also contributes the first nonanecdotal
estimates of the extent to which the contraceptive exclusion
for religious employers inhibits women’s access to the
contraceptive of their choice. We interpret these results with
caution, however, given the between-quarter fluctuations in
the percentage of women denied IUD coverage due to the
exclusion. We might expect that as the share of women
without coverage declines, the proportion of uncovered
women subject to the religious exclusion would increase, but
we observe the opposite, with a higher proportion of women
without coverage affected by the religious exclusion in the
first quarter of 2013 than in the first quarter of 2014.
Between 2006 and 2010, unintended pregnancy rates
declined in all but 2 of the 41 states for which data are
available [25]. This decline corresponded with a national
increase in long-acting reversible contraceptive (LARC) use,
predominantly of the IUD, from 3.7% in 2007 to 8.5% in
2009 [26]. As noted earlier, IUD use has since risen further,
reaching 10% in 2011–2013 [3], and prior research shows
that eliminating costs can lead to increased LARC use, which
in turn can contribute to lower pregnancy, abortion and birth
rates [8,9,12]. Other factors may also contribute to the
decline in unintended pregnancy. However, if the ACA leads
to additional uptake, this may contribute to continued
declines in unintended pregnancy.
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